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AbSTRAKT
H epatic fibrosis is the final stage of many disorders of the liver. Originally, hepatic fibrosis was con­sidered irreversible, however, hepatic fibrosis is now known to be a dynamic process with a sig­
nificant potential for resolution. Timely diagnosis of liver fibrosis can prevent development of unwant­
ed complications. The diagnosis and quantitation of fibrosis have traditionally relied on liver biopsy. 
However, there are a number of drawbacks that limit its use. This article reviews the current methods 
of assessment of hepatic fibrosis based on the serum markers.
Key  w ords:fibrosis of liver; serum markers.
Журавлёва А.К., 
Огнева Е.В., 
Журавлёва Л.В.
ПОДХОД К  ДИАГНОСТИКЕ 
ФИБРОЗА ПЕЧЕНИ: 
СЫВОРОТОЧНЫЕ МАРКЕРЫ
Ж ур ав л ё в а  А н н а  К он стан ти н о вн а,
к.м.н, ассист ент  кафедры внут ренней м едицины  № 3  
Харьковский национальный медицинский университет, кафедра внутренней медицины № 3, 
пр.-т Ленина 4, г. Харьков, 61022, Украина; E-mail: vnmed3@gmail.com 
О гн ева  Е л ен а В ал ен ти н о вн а, к.м.н, ассист ент  кафедры внут ренней м едицины  № 3  
Харьковский национальный медицинский университет, кафедра внутренней ме-дицины № 3,
проспект Ленина 4, г. Харьков, 61022, Украина 
Ж ур ав л е в а  Л ар и са  В л ад и м и р овн а, докт ор м едицинских наук, профессор, заведующ ая  
кафедрой внут ренней м едицины  N 3 Х арьковского национального м едицинского Университ ет а  
кафедра внутренней медицины N3; пр.-т Ленина 4, г. Харьков, 61022, Украина; E-mail: l.zhuravlyova@mail.ru
Ah i
Ф ;
НОТАЦИЯ
иброз печеночной ткани является завершающей стадией развития различ-ных заболеваний пече- 
'ни. Первоначально считалось, что фиброз необратим, но в настоящее время уже известно, что это 
динамический процесс, имеющий значи-тельный потенциал для обратного развития. Своевремен­
ная диагностика фиброза печени может предотвратить возникновение нежелательных осложнений. 
Традиционно диагностика и количественное определение фиброзированной ткани основывались на 
биопсии печени. Но у пункционной биопсии существует целый ряд недостатков, ограничивающих 
проведение этой процедуры. В данной статье рассматриваются современные методы оценки фиброза 
печени, основанные на определении сывороточных маркеров.
ю ч е в ы е  слова: сфиброз печени, сывороточные маркеры.
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Hepatic fibrosis is the final stage of many dis­
orders of the liver. Originally, hepatic fibrosis was 
considered irreversible, however, hepatic fibro­
sis is now known to be a dynamic process with a 
significant potential for resolution. The diagno­
sis of chronic diffuse liver diseases, especially in 
the early stages of the development of histolog­
ical changes is a rather complex problem. Early 
diagnosis of liver fibrosis is very important, since 
the initial stages of fibrosis are reversible and 
timely initiation of treatment will help prevent 
further progression of the process and the devel­
opment of unwanted complications.
Hepatic fibrosis occurs in response to almost 
all causes of chronic liver injury. Hepatic fibro­
sis can occur in response to viral, immune, and 
toxic-metabolic insults and consists of an accu­
mulation of fibrillar extracellular matrix (ECM) 
components. This process may ultimately lead 
to cirrhosis with its consequences of portal hy­
pertension, hepatocellular carcinoma, and liver 
failure [1]. There is a relationship between the 
value of liver stiffness and various complications 
of cirrhosis, such as esophageal varices, variceal 
bleeding, portal hypertension, ascites, and hepa­
tocellular carcinoma [2]. Significant discoveries 
into the mechanisms of hepatic fibrosis progres­
sion and regression have uncovered a number of 
potential targets for antifibrotic drugs.
The gold standard for the diagnosis of his­
tological changes of the liver is a liver biopsy. 
However, its widespread use in practice is lim ­
ited since it does not satisfy quality criteria as a 
surrogate end-point marker because of its com­
plication rate, sampling error, intra- and in­
terobserver variability, expense, and patient re­
luctance to undergo serial monitoring. But with 
drugs that have the potential to reverse hepatic 
fibrosis imminent, a simple, noninvasive, repro­
ducible method of assessing fibrosis is essential 
to monitor disease progression, clinical out­
comes, and response to treatment [3]. This was 
the basis for the introduction into clinical prac­
tice of noninvasive diagnosis of liver fibrosis.
Our deeper understanding of the mechanisms 
of fibrosis has led to the identification of many 
potential markers of fibrosis, which appear ca­
pable of identifying early and advanced hepatic 
fibrosis. Standard cross-sectional imaging stud­
ies will only identify or exclude advanced fibrosis
[4]. Novel technologies such as transient hepatic
elastography and magnetic resonance imaging 
(MRI) elastography show promise as noninva- 
sive methods of testing for hepatic fibrosis but 
they have small value in identifying early stages 
of fibrosis and low-grade inflammation. There 
is also a significant degree of subjectivity in the 
pathologic assessment of liver biopsy samples. A  
number of staging systems have been developed 
to reduce both the interobserver and intraob­
server variability, including the METAVIR, the 
Knodell fibrosis score (later modified by Ishak), 
and the Scheuer score. Most studies have shown 
excellent inter- and intraobserver reproducibili­
ty for the staging of fibrosis. However, the repro­
ducibility of hepatic inflammatory activity is not 
as consistent [1].
A  large number of putative serum markers 
have been evaluated for the assessment of he­
patic fibrosis. Despite the dynamic nature of he­
patic fibrogenesis, most of the presumed tests 
are suitable for the cross-sectional diagnosis of 
fibrosis stage rather than determining the rate of 
fibrosis progression or regression. No true serum 
marker that would act as a surrogate marker of 
hepatic fibrosis has been validated to date. It is 
almost certain that combinations of biomarkers 
will probably have to be examined [2].
Broadly speaking, serum markers of hepatic 
fibrosis can be considered in 1 of 2 categories: 
either indirect or direct. Indirect markers re­
flect alterations in hepatic function but do not 
directly reflect hepatic ECM metabolism, for ex­
ample, platelet count, coagulation studies, and 
hepatic aminotransferases. Direct serum assays 
for markers of fibrosis reflect serum ECM turn­
over. The discovery of many of these direct bio­
markers is directly attributable to advances in 
the understanding of the molecular mechanisms 
involved in hepatic fibrogenesis. Serum assays 
for enzymes and products of matrix synthesis or 
degradation have been evaluated as markers of 
fibrosis in many studies and show some promise 
as a simple alternative to liver biopsy [3].
From indirect markers serum alaninamino- 
transferase (ALT) levels indicate liver inflamma­
tion, and high inflammatory activity is always ac­
companied by fibrogenesis. That is why high lev­
els of ALT in serum are considered to have high 
rates of specificity and sensitivity on histological 
features of inflammatory activity and liver fibro­
sis. It was established that the increase of ALT
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more than 2.5 times of the normal range reflects 
histological changes corresponding to A1-F1 in 
28% of patients, while at the same time 26% of 
patients with the same histological features A1- 
F1 have normal ALT levels. The level of aspartat- 
aminotransferase (AST) has stronger correlation 
with fibrosis than ALT. Thus ratio AST/ALT>1 is 
a likely indicator of severe stages of fibrosis and 
cirrhosis. Ratio AST/ALT>1.16 with sensitivity 
of 81.3% and a specificity of 55.3% predicts the 
presence of cirrhosis. Combination of AST/ALT 
ratio with platelet levels contributes to its diag­
nostic value as it is known that thrombocytope­
nia is a marker of liver cirrhosis [2, 5, 6].
Advancing liver fibrosis is associated with re­
duced thrombopoetin production and increased 
platelet sequestration in the spleen and also with 
reduced clearance of AST. The AST to platelet 
ratio index (APRI) is easy available simple index 
and is calculated as follows: APRI = (AST/upper 
limit of normal) x 100/platelet count. A  recent 
meta-analysis of 22 studies, predominantly in­
volving chronic HCV patients, made a number of 
observations. At an APRI threshold of 0.5, the 
sensitivity and specificity for significant fibro­
sis were 81% and 50%, respectively. At an APRI 
threshold of 1, the sensitivity and specificity for 
predicting cirrhosis were 76% and 71%, respec­
tively [1, 6, 7].
Direct markers of liver fibrosis include a 
number of serum or urinary markers, which 
have been shown to be or are thought to be in­
volved in the deposition of ECM. Liver fibro­
sis involves both quantitative and qualitative 
changes in ECM markers. Because some of the 
markers reflect fibrosis progression and others 
fibrosis regression, it is thought that a dynamic 
evaluation of ECM activity should be possible. 
Potential markers of fibrosis include products 
of collagen synthesis or degradation, enzymes 
involved in matrix biosynthesis or degradation, 
ECM glycoproteins, and proteoglycans/glycos­
aminoglycans. None of the currently available 
direct biomarkers completely fulfills the criteria 
for an ideal biomarker because none is liver spe­
cific and most are affected by changes in their 
metabolism, clearance, or excretion. But as fi­
brosis can occur in other organs of the body these 
markers are not specific for liver involvement in 
the process. And because of their determination 
is rather expensive and not every laboratory has
an opportunity to perform this these markers are 
not used in routine doctor’s practice [1, 8].
In recent years there have been developed 
diagnostic indexes based on a combination of 
biochemical markers of liver fibrosis to improve 
the diagnostic value of various laboratory tests. 
The first group of the most widely used diagnostic 
panels was FibroMaks (BioPredictive, France).
Diagnostic panels FibroTest, FibroMaks and 
designed by French hepatologists and are an ex­
pert system based on the calculation of these 
biochemical parameters of blood: ALT, AST, 
gammaglutamiltranspeptidase (GGTP), total 
bilirubin, cholesterol, apolipoprotein A1, fast­
ing glucose, gaptoglobin, а-2-macroglobulin, 
triglycerides [9].
FibroTest includes 2 calculation algorithms -  
Fibrotest for the diagnosis of liver fibrosis and 
Aktitest to assess the necroinflammatory activi­
ty, and the panel FibroMaks in addition includes 
diagnostic algorithms Steatotest to determine 
the stage of steatosis, Ashtest to determine the 
degree of activity of alcoholic steatohepatitis 
and Nashtest to evaluate the stage of nonalco­
hol steatohepatitis in patients with metabolic 
syndrome. According to the prospective study 
of liver biopsies its number decreased by 46% 
through the use FibroMaks [10].
Fibrotest has a lot of advantages over the 
other methods of liver diagnosis. FibroTest is a 
low invasive procedure -  patient just needs to 
donate blood from vein. In biopsy the biomate­
rial is taken from only one area and there is a 
chance that the bioptate will be obtained from a 
relatively healthy portion, as fibrosis affects the 
liver heterogeneously, and FibroTest allows you 
to make a comprehensive assessment of the en­
tire liver condition. FibroTest detects function­
al disorders of liver even before the significant 
morphological defects are formed which makes 
possible finding of the earliest stages of fibrosis. 
FibroTest is indispensable when it is impossible 
to perform a biopsy on any clinical indications, 
such as disturbances of the blood coagulation 
system [9, 10].
In the pathology of metabolic syndrome in the 
absence of fibrosis and steatosis the observation 
is recommended every 1 -  2 years. In the presence 
of fibrosis, which is a consequence of steatosis 
or steatohepatitis an appropriate treatment and 
control is recommended every 3 -  4 months.
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Application of FibroTest will give false-pos­
itive or false-negative results at acute hepatitis, 
extrahepatic cholestasis, Gilbert’s syndrome, 
acute hemolysis, acute inflammation, in patients 
with liver transplants. Also FibroTest has disad­
vantages such as restrictions on carrying out the 
test in most of laboratories as they do not meet 
the requirements of the developer system and 
relative high cost of research [11].
Diagnostic panel SteatoScreen allows to de­
tect the risk of development of fibrosis and/or 
steatosis in different groups of patients and can 
be considered as a routine test for initial diag­
nostics of histological activity of pathological 
processes in liver. SteatoScreen test consists of 
1 calculation algorithm and is performed on the 
results of mathematical processing of the same 
10 biochemical blood indexes which are required 
for the FibroTest.
Fibrometer is a system of tests that are also 
based on the calculation of the index using math­
ematical data of biochemical blood parameters. 
This system consists of three sets of tests that are 
used depending on the etiology of the disease.
Fibrometer A is performed for suspected alcohol 
etiology of the disease and is not used for the di­
agnosis in case of combined etiology. Fibrometer 
V  is used in the presence of chronic viral hepati­
tis as an isolated pathology, and when combined 
with alcohol etiology and/or within NAFLD. Fi­
brometer S is applied in case of fatty liver disease 
and metabolic syndrome, as well as in combina­
tion with alcoholic etiology. The limitations of 
using this panel are the age under 18 years, acute 
hepatitis, kidney failure, pregnancy, and during 
treatment of liver disease [12].
The difference between the FibroTest and Fi- 
brometer systems is there different visual eval­
uation (Pic. 1). The FibroTest is presented as a 
sole scale that represents the stage of the pro­
cess, and the results of Fibrometer are presented 
in the form of double circular scales: the inner 
scale shows the stage of the process (by META- 
VIR system) and the outer line represents an in­
dex that indicates the amount fibrotic tissue. In 
both systems the results are performed from 0 to 
1 (or in the percent) and indicate the volume of 
fibrotic tissue [11, 12].
FibroTest
0 .7 5 -
0 . 5 Q - -
0 .2 5 -
0 . 0 0 1
-  -
ы
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-  - F2
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Pic.1. FibroTest and Fibrometer scales
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There are some more tests for evaluation of 
morphological liver state. The scale CirrhoM- 
eter allows to characterise the revealed fibrosis 
more accurately using the 3rd and the 4th stages 
by METAVIR. The scale InflaMeter allows a de­
tailed assessment of necroinflammatory changes 
in liver. The scale shows the index and the stage 
of histological activity of the process [12]
Although liver biopsy remains the gold stan­
dard for assessment of liver fibrosis it does not 
meet all the requirements because of its poten­
tial for complications, the significant sampling
error and interobserver variability. Liver biopsy 
is not considered as a procedure used to monitor 
the treatment of patients and progression or re­
gression of fibrotic processes. Assessment of liv­
er fibrosis with multiple serum markers used in 
combination is sensitive, specific, and reproduc­
ible, suggesting they may be used in conjunction 
with liver biopsy to assess a range of chronic liv­
er diseases. Noninvasive panels are suitable for 
assessing and particularly quantifying fibrosis 
but still not sensitive enough to measure small 
changes in the state of the ECM.
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